tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
PremiumThe FlyMineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
2M ago
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
Premium
Ratings
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
2M ago
Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
Premium
Ratings
Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
2M ago
Mineralys Therapeutics announces $175M common stock offering
PremiumThe FlyMineralys Therapeutics announces $175M common stock offering
2M ago
3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
2M ago
Jefferies expects Mineralys stock to trade up following AstraZeneca data
Premium
The Fly
Jefferies expects Mineralys stock to trade up following AstraZeneca data
2M ago
Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position
PremiumRatingsPositive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position
3M ago
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond
Premium
Ratings
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond
3M ago
Mineralys Therapeutics Reports Positive Q2 2025 Results
Premium
Company Announcements
Mineralys Therapeutics Reports Positive Q2 2025 Results
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100